CEO Ana Slipicevic present the MTHFD2 program and one-carbon therapeutics AB in the Hot Topic session at Bio€quity 2022 in Milan.
The MTHFD2 program is pitched by CEO Dr Ana Slipicevic at the Meet2Win conference in Bordeaux and wins a pitch price!
One-carbon therapeutics AB is granted 3,000,000 SEK from Sweden’s innovation agency Vinnova under the Medtech4Health and SweLife programs for further development of the MTHFD2 program.
We are proud that the MTHFD2 inhibitors are now published in the prestigious journal Nature Cancer. In this first report, we describe that MTHFD2 inhibitors deplete cells of thymidine, specifically in cancer cells. We show that the loss of thymidine causes replication...
We are very pleased to announce that Dr Ana Slipicevic has been appointed as acting CEO of one-carbon therapeutics AB. Ana is joining us from Oncopeptides AB where she has been translational research director and leading a team developing and implementing...
One-carbon therapeutics AB receives SME status by EMA The incentives offered by the SME Regulation give access to: Regulatory assistance: SMEs can benefit from direct regulatory assistance including SME briefing meetings, to provide guidance on the EU regulatory...
Eir Ventures grants one-carbon a convertible loan to continue pre-seed activities in company and at the same time Magnus Persson becomes the new chairman and Alexander Mata joins the board of directors.
One-carbon is receiving a seed investment from its founders to strengthen the financial situation and secure continuous pre-clinical development of MTHFD2 inhibitors.
Prof Thomas Helleday presents MTHFD2 and other emerging targets such as PKMYT1, MTH1 and Pol Theta at the AACR21 virtual meeting